An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection
Hantaviruses, etiologic pathogens responsible for two severe human diseases, exist in areas ranging from Eurasia to America and remain global public health concerns. Conventionally, plaque formation assays have been used for hantavirus titering. However, hantaviruses replicate slowly within cells and produce minimal cytopathic effects, making this technique difficult to master. The improved enzyme-linked immunosorbent assay-based antigen detection method is easier to perform but is still time consuming. Here, we established an enzyme-linked focus formation assay (FFA) for Hantaan virus titering that is twice as fast as traditional assays. Moreover, using this method, we evaluated the effects of favipiravir (T-705) and another influenza virus drug, baloxavir acid (BXA), on hantavirus replication. We found that the endonuclease inhibitor BXA exerted similar anti-hantavirus effects as T-705. Overall, we developed a time-saving method for hantavirus titering and suggest BXA as a potential treatment choice for hantavirus-exposed individuals..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 10(2019) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chuantao Ye [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BXA |
|---|
| doi: |
10.3389/fphar.2019.01203 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ014946491 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ014946491 | ||
| 003 | DE-627 | ||
| 005 | 20230310071925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2019.01203 |2 doi | |
| 035 | |a (DE-627)DOAJ014946491 | ||
| 035 | |a (DE-599)DOAJ37ee94965e474625a861481c7a10b12c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Chuantao Ye |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hantaviruses, etiologic pathogens responsible for two severe human diseases, exist in areas ranging from Eurasia to America and remain global public health concerns. Conventionally, plaque formation assays have been used for hantavirus titering. However, hantaviruses replicate slowly within cells and produce minimal cytopathic effects, making this technique difficult to master. The improved enzyme-linked immunosorbent assay-based antigen detection method is easier to perform but is still time consuming. Here, we established an enzyme-linked focus formation assay (FFA) for Hantaan virus titering that is twice as fast as traditional assays. Moreover, using this method, we evaluated the effects of favipiravir (T-705) and another influenza virus drug, baloxavir acid (BXA), on hantavirus replication. We found that the endonuclease inhibitor BXA exerted similar anti-hantavirus effects as T-705. Overall, we developed a time-saving method for hantavirus titering and suggest BXA as a potential treatment choice for hantavirus-exposed individuals. | ||
| 650 | 4 | |a viral nucleic acid synthesis inhibitors | |
| 650 | 4 | |a hantavirus | |
| 650 | 4 | |a FFA | |
| 650 | 4 | |a T-705 | |
| 650 | 4 | |a BXA | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Chuantao Ye |e verfasserin |4 aut | |
| 700 | 0 | |a Dan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a He Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Hongwei Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Yangchao Dong |e verfasserin |4 aut | |
| 700 | 0 | |a Min Yao |e verfasserin |4 aut | |
| 700 | 0 | |a Yuan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Hui Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Liang Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Linfeng Cheng |e verfasserin |4 aut | |
| 700 | 0 | |a Zhikai Xu |e verfasserin |4 aut | |
| 700 | 0 | |a Yingfeng Lei |e verfasserin |4 aut | |
| 700 | 0 | |a Fanglin Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Wei Ye |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 10(2019) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2019.01203 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/37ee94965e474625a861481c7a10b12c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fphar.2019.01203/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 | ||